Lilly reports strong fourth quarter on rising sales of Trulicity, Taltz
The Indianapolis-based drugmaker exceeded analyst expectations for both profit and revenue during the most recent quarter.
Eli Lilly and Co.
Articles
Lilly to build $470M manufacturing plant in North Carolina
Eli Lilly and Co. said it considered sites in Indianapolis and Pennsylvania but chose North Carolina for quality of life, cost of operations and geographical diversity.
Lilly kills R&D deal in speed bump on quest to become big cancer player
The Indianapolis drugmaker quietly terminated a collaboration with NextCure Inc. after spending $40 million on an up-front fee and equity investment, and with little to show from the partnership.
$1.1B acquisition would give Lilly more skin in immunology game
Analysts have said that Dermira’s lead pipeline product, lebrikizumab, has the potential to be the best in class among a wave of similar antibodies to treat eczema.
Lilly wins another patent infringement case over cancer drug Alimta
Alimta is Lilly’s third-best-selling drug, with global sales of $2.1 billion last year. The court ruling stops a Canadian competitor from launching a generic version of the drug before its patent expires in 2022.
To raise cash, Lilly Endowment unloads more Eli Lilly stock
For the Lilly Endowment, a good year means it’s time to cash in.
Lilly launches awareness campaign for insulin discount options
Under fire from politicians, patients and health care advocates over the price of insulin, Eli Lilly and Co. announced a campaign Thursday morning to raise awareness of cost-saving options for the drug.
Eli Lilly to spend $400M on manufacturing expansion in Indy, add 100 jobs
The pharmaceutical giant says it needs additional manufacturing capacity to keep up with demand for current medicines and new drugs expected to emerge from its pipeline.
Eli Lilly CEO says drugmaker won’t rehash old Alzheimer’s data
Digging through old data to salvage a seemingly failed Alzheimer’s drug paid off big time for Biogen Inc., but at least one of its rivals has no plans to follow suit.
Lilly earns more than expected but misses revenue expectations on key drugs
Eli Lilly and Co. easily topped earnings expectations in the third quarter, but shares in the Indianapolis-based drug company tumbled nearly 5 percent Wednesday morning.
In surprise turnaround, new analysis finds Alzheimer’s treatment might work
Seven months after clinical trials for a promising Alzheimer’s drug were halted and the treatment was declared a failure, a new analysis suggests it was actually effective, and the company that makes it plans to move forward in securing federal approval.
Lilly experimental drug fails in late-stage trial for pancreatic cancer
The drug, called pegilodecakin, had been seen as a promising treatment for one of the deadliest types of cancer, and was the lead product in Lilly’s $1.6 billion acquisition of Armo BioSciences last year.
Lilly’s hot-selling Taltz approaching blockbuster status
Last year, Taltz rang up sales of $937.5 million, and doctors are increasingly prescribing it. For the first six months of this year, Taltz recorded $606.3 million in sales, putting it on pace to break the $1 billion threshold, perhaps in the third quarter.
Elanco says it’s buying Bayer division for $7.6 billion
The purchase would swell Elanco from the world’s fourth-largest animal health player to the second-largest, behind only New Jersey-based Zoetis.
Trump’s Canada drug import plan can’t happen without Big Pharma
President Donald Trump’s plan to import cheap Canadian drugs overlooks a crucial fact: Canada’s pharmaceutical supply chain is beholden to the drugmakers.
Elanco in advanced talks to buy Bayer animal-health unit, report says
The multibillion-dollar deal would swell the size of Elanco, which already is the fourth-largest global player in animal health.
Eli Lilly tops quarterly expectations, raises forecast
A jump in sales from the diabetes treatment Trulicity helped push the Indianapolis-based drugmaker to a better-than-expected second quarter.
Trump kills key drug price proposal he once embraced
The drug rebate rule would have ended a widespread practice in which drugmakers give rebates to insurance middlemen in government programs such as Medicare. The idea was to channel that money to consumers instead.
Lilly losing two senior executives, including Bio-Medicines chief
Lilly shares dropped 4.6 percent in early trading after the company said Christi Shaw was leaving and Mike Harrington planned to retire.
Judge strikes down rule requiring drug ads to reveal prices
Responding to a lawsuit by Eli Lilly and two other companies, a federal judge Monday blocked a major White House initiative on prescription drug costs, saying the Trump administration lacked the legal authority to require drugmakers to disclose their prices in TV ads.